The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPα DNA binding via leucine zipper domain interaction
Abstract
Transcription factor C/EBPalpha induces normal myeloid differentiation, inactivation of C/EBPalpha leads to a differentiation block in acute myeloid leukemias (AML), and overexpression of C/EBPalpha results in AML growth arrest and differentiation. Recent reports suggest that C/EBPalpha is activated or inactivated via protein-protein interactions. We previously reported that C/EBPalpha needs to inactivate the proto-oncogene c-Jun via leucine zipper domain interaction in order to induce granulocytic differentiation. We, therefore, hypothesized that c-Jun expression might be elevated in AML and subsequently inactivate C/EBPalpha. In fact, compared to normal bone marrow mononuclear cells, c-Jun expression is increased in AML patient samples (Affymetrix expression microarray analysis, n=166). c-Jun binds to C/EBPalpha via the leucine zipper domains and prevents C/EBPalpha from DNA binding. Inactivation of C/EBPalpha by c-Jun is necessary for c-Jun to induce proliferation because c-Jun-induced proliferation can be prevented by ectopic overexpression of C/EBPalpha. The dominant-negative 30-kDa C/EBPalpha protein, found in AML, fails to downregulate c-Jun mRNA expression in AML patient samples. Thus, our data suggest a model for AML in which c-Jun promotes proliferation and prevents differentiation by inhibiting C/EBPalpha DNA binding via leucine zipper domain interaction. It might depend on the expression levels of C/EBPalpha and c-Jun, if inhibition of C/EBPalpha by c-Jun or if inhibition of c-Jun by C/EBPalpha is more predominant: proliferation versus differentiation; AML versus normal myeloid development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Different studies in several human neoplasms [50–53], including CRC [54], showed higher c-JUN expression and activation in tumors compared to normal tissue.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [51]
Citations
Cites
AP-1 as a regulator of cell life and death
Shaulian, E., & Karin, M. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e131 · Cited by 2,961
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In contrast, the transcription factor C/EBPa is necessary for normal myeloid differentiation (Zhang et al., 1997; Porse et al., 2001), inactivation of C/EBPa can lead to myeloid leukemia (Pabst et al., 2001a,b; Perrotti et al., 2002; Schuster et al., 2002), and overexpression of C/EBPa in AML leads…”
BackgroundSelf-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901 · cited 7×
“…by BCR-ABL (Perrotti et al., 2002; Schuster et al., 2003), AML1-ETO (Pabst et al., 2001a), PML-RARa (Truong et al., 2003), and through mutation (Pabst et al., 2001b), thus being a common target in myeloid leukemias, we hypothesized that elevated c-Jun expression in AML might inactivate C/EBPa…”
BackgroundSelf-citationDisruption of differentiation in human cancer: AML shows the way
Tenen, D. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc989 · Cited by 612
Self-citationPreudhomme, C., Sagot, C., Boissel, N., Cayuela, J.-M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0990 · Cited by 501
Radomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466
Self-citationAML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G. (2001) · Nature Medicine · doi:10.1038/86515 · Cited by 463 · cited 7×
“…by BCR-ABL (Perrotti et al., 2002; Schuster et al., 2003), AML1-ETO (Pabst et al., 2001a), PML-RARa (Truong et al., 2003), and through mutation (Pabst et al., 2001b), thus being a common target in myeloid leukemias, we hypothesized that elevated c-Jun expression in AML might inactivate C/EBPa…”
BackgroundSelf-citationNegative cross-talk between hematopoietic regulators: GATA proteins repress PU.1
Zhang, P., Behre, G., Pan, J., Iwama, A., Wara-aswapati, N., Radomska, H. S., Auron, P. E., Tenen, D. G., & Sun, Z. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8705 · Cited by 459
Self-citationC/EBPα Arrests Cell Proliferation through Direct Inhibition of Cdk2 and Cdk4
Wang, H., Iakova, P., Wilde, M., Welm, A., Goode, T., Roesler, W. J., & Timchenko, N. A. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00366-5 · Cited by 355
E2F Repression by C/EBPα Is Required for Adipogenesis and Granulopoiesis In Vivo
Porse, B. T., Pedersen, T. Å., Xu, X., Lindberg, B., Wewer, U. M., Friis-Hansen, L., & Nerlov, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00516-5 · Cited by 317
BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2
Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., Iervolino, A., Condorelli, F., Gambacorti-Passerini, C., Caligiuri, M. A., et al. (2002) · Nature Genetics · doi:10.1038/ng791 · Cited by 313
Gombart, A. F., Hofmann, W.-K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S. H., Larsen, R. J., Asou, H., Miller, C. W., Hoelzer, D., et al. (2002) · Blood · doi:10.1182/blood.v99.4.1332 · Cited by 293 · cited 1×
“…expression C/EBPa mutants, mostly encoding a 30-kDa form that acts dominant negative to wild-type 42-kDa C/EBPa on the second allele, have been described before in around 13% of AML (Pabst et al. , 2001b; Gombart et al., 2002; Preudhomme et al., 2002; Waalwijk Van DoornKhosravani et al., 2002).”
BackgroundSchoch, C., Kohlmann, A., Schnittger, S., Brors, B., Dugas, M., Mergenthaler, S., Kern, W., Hiddemann, W., Eils, R., & Haferlach, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142103599 · Cited by 274
Self-citationVangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245 · cited 8×
“After being activated, C/EBPa inactivates the transcription factor PU.1 via direct protein–protein interaction to prevent dendritic and Received 11 January 2003; revised 27 March 2003; accepted 27 March 2003 *Correspondence: G Behre, Medicine III at University of Munich Hospital Grosshadern, Marchioninistr.”
BackgroundSelf-citationHeterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
Self-citationc-Jun Is a JNK-independent Coactivator of the PU.1 Transcription Factor
Behre, G., Whitmarsh, A. J., Coghlan, M. P., Hoang, T., Carpenter, C. L., Zhang, D.-E., Davis, R. J., & Tenen, D. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.4939 · Cited by 180 · cited 1×
“C/EBPa interaction (Truong et al., 2003), but also as a driving force in the context of lineage commitment and normal differentiation, such as PU.1–c-Jun interaction (Behre et al., 1999), PU.1–”
BackgroundSelf-citationMcBindall—A Better Name for CCAAT/Enhancer Binding Proteins?
McKnight, S. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00543-8 · Cited by 170 · cited 1×
“Most interestingly, protein–protein interactions are not only responsible for inactivation of C/EBPa in AML, but also C/EBPa itself seems to function via protein–protein interactions (McKnight, 2001).”
BackgroundReddy, V. A., Iwama, A., Iotzova, G., Schulz, M., Elsasser, A., Vangala, R. K., Tenen, D. G., Hiddemann, W., & Behre, G. (2002) · Blood · doi:10.1182/blood.v100.2.483 · Cited by 152 · cited 2×
“15, D-81377 Munich, Germany; E-mail: gerdbehre@aol.com Oncogene (2003) 22, 4760–4764 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc monocytic cell differentiation (Iwama et al., 2002; Reddy et al., 2002).”
Self-citationRecruitment of p300 by C/EBPβ triggers phosphorylation of p300 and modulates coactivator activity
Schwartz, C., Schachtrup, K., Mink, S., Schmolke, M., Budde, B., Wenning, D., & Klempnauer, K.-H. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg076 · Cited by 122
Iwama, A., Osawa, M., Hirasawa, R., Uchiyama, N., Kaneko, S., Onodera, M., Shibuya, K., Shibuya, A., Vinson, C., Tenen, D. G., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011465 · Cited by 115 · cited 1×
“15, D-81377 Munich, Germany; E-mail: gerdbehre@aol.com Oncogene (2003) 22, 4760–4764 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc monocytic cell differentiation (Iwama et al., 2002; Reddy et al., 2002).”
Self-citationCCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia
Truong, B.-T. H., Lee, Y.-J., Lodie, T. A., Park, D. J., Perrotti, D., Watanabe, N., Koeffler, H. P., Nakajima, H., Tenen, D. G., & Kogan, S. C. (2002) · Blood · doi:10.1182/blood-2002-05-1374 · Cited by 112 · cited 5×
“C/EBPa interaction (Truong et al., 2003), but also as a driving force in the context of lineage commitment and normal differentiation, such as PU.1–c-Jun interaction (Behre et al., 1999), PU.1–”
BackgroundC/EBPα triggers proteasome‐dependent degradation of cdk4 during growth arrest
Wang, H., Goode, T., Iakova, P. A., Albrecht, J. H., & Timchenko, N. A. (2002) · The EMBO Journal · doi:10.1093/emboj/21.5.930 · Cited by 103
Behre, G., Singh, S. M., Liu, H., Bortolin, L. T., Christopeit, M., Radomska, H. S., Rangatia, J., Hiddemann, W., Friedman, A. D., & Tenen, D. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202301200 · Cited by 90 · cited 1×
“We previously reported that C/ EBPa is functionally activated by the Ras signal transduction pathway via phosphorylation on serine 248 (Behre et al., 2002).”
BackgroundSelf-citationRangatia, J., Vangala, R. K., Treiber, N., Zhang, P., Radomska, H., Tenen, D. G., Hiddemann, W., & Behre, G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8681-8694.2002 · Cited by 62
Self-citationSchuster, C., Forster, K., Dierks, H., Elsässer, A., Behre, G., Simon, N., Danhauser-Riedl, S., Hallek, M. J., & Warmuth, M. (2002) · Blood · doi:10.1182/blood-2002-01-0043 · Cited by 51 · cited 2×
“Furthermore, the fusion protein BCR-ABL in chronic myeloid leukemia (Perrotti et al., 2002; Schuster et al., 2003) and AML-specific Flt3 mutations (Mizuki et al., 2002) downregulate C/EBPa expression.”
BackgroundSelf-citationZada, A. A. P., Singh, S. M., Reddy, V. A., Elsässer, A., Meisel, A., Haferlach, T., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206393 · Cited by 51 · cited 3×
“In fact, overexpression of c-Jun induced proliferation in AML cell lines, measured by Trypan blue cell counting (Peer Zada et al., 2003), brdU assay (Peer Zada et al., 2003), and CD71 FACS analysis (Figure 2a).”
BackgroundMethodSelf-citationBurgess, G. S., Williamson, E. A., Cripe, L. D., Litz-Jackson, S., Bhatt, J. A., Stanley, K., Stewart, M. J., Kraft, A. S., Nakshatri, H., & Boswell, H. S. (1998) · Blood · doi:10.1182/blood.v92.7.2450 · Cited by 47
Burgess, G. S., Williamson, E. A., Cripe, L. D., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2450.2450_2450_2460 · Cited by 7
van Doorn-Khosrovani, S. B. V. W., Erpelinck-Verschueren, C. A. J., Meijer, J. M., van Oosterhoud, S., van Putten, W. L. J., Valk, P. J. M., Beverloo, H. B., Tenen, D. G., Löwenberg, B., & Delwel, R. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200214 · Cited by 6
Self-citation
Research works printed but not linked: 1
- Elsaesser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Update.Schoch C, Reddy V, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W and Behre G . (2003). Oncogene, in press.
Cited by
Corces, M. R., Buenrostro, J. D., Wu, B., Greenside, P. G., Chan, S. M., Koenig, J. L., Snyder, M. P., Pritchard, J. K., Kundaje, A., Greenleaf, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3646 · Cited by 1,151
Transcriptional control of granulocyte and monocyte development
Friedman, A. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210764 · Cited by 427
“Similarly, C/EBPa binds c-Jun, but not if the LZ is deleted from either of these proteins, and c-Jun inhibits C/EBPa DNA-binding (Rangatia et al., 2002, 2003).”
BackgroundEmerging roles of ATF2 and the dynamic AP1 network in cancer
Lopez-Bergami, P., Lau, E., & Ronai, Z. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2681 · Cited by 350
The functional contrariety of JNK
Bode, A. M., & Dong, Z. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20348 · Cited by 293
“found in bone marrow of acute myeloid leukemia patients [50] and JNKs activity was reported to be high in leukocytes isolated from patients with adult”
BackgroundMariani, O., Brennetot, C., Coindre, J.-M., Gruel, N., Ganem, C., Delattre, O., Stern, M.-H., & Aurias, A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.007 · Cited by 211
Metadata
- Authors
- Rangatia, J., Vangala, R. K., Singh, S. M., Peer Zada, A. A., Elsässer, A., Kohlmann, A., Haferlach, T., Tenen, D. G., Hiddemann, W., & Behre, G.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Harvard University (US)
- Corresponding author
- Behre, Gerhard
- Venue
- Oncogene
- Published
- 2003-07-24
- Volume
- 22
- Issue
- 30
- Pages
- 4760-4764
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2009516725
- Cited by
- 62
- References
- 28
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 2 · 2013: 5 · 2012: 1
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- c-Jun, C/EBPα, acute myeloid leukemia, leucine zipper domain, protein-protein interaction, DNA binding inhibition, myeloid differentiation, leukemia cell proliferation, transcription factor inactivation
- MeSH terms
- Proto-Oncogene Mas, Cell Differentiation, Cell Division, DNA, Flow Cytometry, Humans, Models, Molecular, Phosphorylation, Protein Binding, RNA, Messenger, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, Down-Regulation, Leucine Zippers, Protein Structure, Tertiary, Oligonucleotide Array Sequence Analysis, Mitogen-Activated Protein Kinases, CCAAT-Enhancer-Binding Protein-alpha, JNK Mitogen-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.